Stockchase Opinions

Robert McWhirter Medwell Capital Corp. MWC-X RISKY Jan 26, 2009

Very interesting biotechnology targeted to MS. Ranks well in his model at 15 because of the strong performance of the stock. Early-stage company.
$3.560

Stock price when the opinion was issued

Consumer Products
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

COMMENT
In phase 3 pivotal trial for secondary progressive MS and about a year away from getting data. Just got FDA approval to start trials in the US. Very high Risk and very high Reward.